重组人血管内皮抑制素注射液同步放化疗治疗局部晚期非小细胞肺癌的临床效果

Clinical effect of Recombinant Human Endostatin Injection combined with concurrent chemoradiotherapy in treatment of locally advanced non-small cell lung cancer

目的观察重组人血管内皮抑制素注射液同步放化疗治疗局部晚期非小细胞肺癌的临床疗效和安全性。方法回顾性分析2017年11月至2020年12月吉首大学第一附属医院肿瘤科行根治性同步放化疗的49例局部晚期非小细胞肺癌患者的临床资料,根据放化疗期间是否予重组人血管内皮抑制素注射液同步治疗,将其分为研究组(23例)和对照组(26例),研究组予重组人血管内皮抑制素注射液同步放化疗治疗,对照组予同步放化疗治疗,比较两组患者的客观有效率、中位无进展生存时间、1年生存率、2年生存率、中位生存时间及放射性肺炎、放射性食管炎、骨髓抑制、消化道反应发生情况。结果研究组与对照组的客观有效率分别为52.2%、69.2%,两组的客观有效率比较,差异无统计学意义(P>0.05);研究组与对照组的中位无进展生存时间分别为8.50、6.13个月,两组的中位无进展生存时间比较,差异无统计学意义(P>0.05);1年生存率分别为91.3%、80.8%,2年生存率分别为53.5%、43.3%,中位生存时间分别为28.70、21.13个月,两组的1年生存率、2年生存率、中位生存时间比较,差异无统计学意义(P>0.05)。两组的放射性肺炎、放射性食管炎、骨髓抑制、消化道反应发生情况比较,差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素注射液同步放化疗与同步放化疗疗效及安全性相当。是否更能改善局部晚期非小细胞肺癌的疗效待进一步研究。

Objective To observe the clinical efficacy and safety of Recombinant Human Endostatin Injection combined with concurrent chemoradiotherapy in treatment of locally advanced non-small cell lung cancer.Methods The clinical data of 49 patients with locally advanced non-small cell lung cancer who received radical concurrent chemoradiotherapy in the Department of Oncology,the First Affiliated Hospital of Jishou University from November 2017 to December 2020 were retrospectively analyzed,they were divided into experimental group(23 cases)and control group(26 cases).Experimental group received Recombinant Human Endostatin Injection concurrent chemoradiotherapy,control group received concurrent chemoradiotherapy.The objective response rate,median times of progression-free survival,1-year progression free survival rates,2-year progression free survival rates,median times of overall survival and the incidence of radiation pneumonitis,radiation esophagitis,bone marrow suppression and digestive tract reaction of two groups were compared.Results The objective response rate of experimental group and control group were 52.2%and 69.2%,respectively.There was no significant difference in the objective response rate between the two groups(P>0.05).The median times of progression-free survival in experimental group and control group were 8.50 months and 6.13 months,respectively.There was no significant difference in median times of progression-free survival between the two groups(P>0.05).The 1-year survival rates were 91.3%and 80.8%,the 2-year survival rates were 53.5%and 43.3%,the median times of overall survival were 28.70 months and 21.13 months,respectively.There were no statistically significant differences in the 1-year survival rate,2-year survival rate and median times of overall survival between the two groups(P>0.05).There was no significant difference in the incidence of radiation pneumonitis,radiation esophagitis,bone marrow suppression and digestive tract reaction between the two groups(P>0.05).Conclusion The efficacy and safety of Recombinant Human Endostatin Injection concurrent chemoradio therapy and concurrent chemoradiotherapy are comparable.Whether Recombinant Human Endostatin Injection concurrent chemoradiotherapy can improve the effect of locally advanced non-small cell lung cancer more than concurrent chemoradiotherapy needs further study.